Program
Our 2026 program will dive deeper into the clinical applications of theranostics in prostate cancer, as well as next-generation targets and ligands shaping the future of oncology. Through detailed case-based discussions, we will highlight the real-world impact of these innovations, providing valuable insights for clinicians across medical oncology, radiation oncology, urology, nuclear medicine and radiology, as well as physicists, laboratory scientists, radiochemists, radiopharmacists, technologists, and nurses alike.
ProsTIC26 Pre-Conference Events
- Thursday 3 September 2026
- Peter MacCallum Cancer Centre
|
9:30 AM - 10:00 AM
|
Consumer Session | Registration & Morning Tea | Location: Level 13 Event Space, PMCC
|
|||||
|---|---|---|---|---|---|---|
|
10:00 AM - 11:45 AM
|
Consumer Session
Location: Level 13 Event Space |
|||||
|
10:00 AM - 10:05 AM
|
Welcome
|
Elizabeth Medhurst
|
||||
|
10:05 AM - 10:20 AM
|
Theranostics 101: How Imaging and Treatment Work Together
|
Michael Hofman
|
||||
|
10:20 AM - 10:35 AM
|
LuPSMA access in Australia: what is the current status and best way forward?
|
|
||||
|
10:35 AM - 10:50 AM
|
Clinical Trials and Next-Generation Radionuclides in Prostate Cancer
Emerging evidence guiding future clinical practice
|
Louise Kostos
|
||||
|
10:50 AM - 11:05 AM
|
What PCFA Offers: Supporting the Prostate Cancer Journey
Advocacy, education, research, and support for Australians affected by prostate cancer |
Russell Briggs
|
||||
|
11:05 AM - 11:20 AM
|
Consumer Q&A
This session will be focus around patient experience on a clinical trial and Lutetium PSMA, given access appears to be limited to trials |
Elizabeth Medhurst
|
||||
|
11:20 AM - 11:40 AM
|
Panel Questions
|
|
||||
|
11:40 AM - 11:45 AM
|
Thank you and Close
|
Elizabeth Medhurst
|
||||
|
12:00 PM - 12:30 PM
|
Nuclear Medicine Technologist Session | Registration & Lunch
Location: Level 7 Atrium |
|
12:00 PM - 12:30 PM
|
PCFA Nurses Session | Registration & Lunch
Location: Level 7 |
||
|
12:30 PM - 2:40 PM
|
Theranostic Masterclass for Nuclear Medicine Technologists | Part 1
Location: Level 7 Atrium |
|
12:30 PM -
2:25 PM |
PCFA Nurses Session | Session 1
Location: Level 13 |
||
|
12:30 PM - 12:35 PM
|
Welcome
|
Michael Hofman
|
|
12:30 PM -
12:35 PM |
Welcome
|
Elizabeth Medhurst
|
|
12:35 PM - 12:40 PM
|
Housekeeping
|
Robert Jamison
|
|
12:35 PM -
12:50 PM |
From Image to Injection
How diagnostics guide precision radionuclide therapy |
Javad Saghebi
|
|
12:40 PM - 12:55 PM
|
Theranostics Landscape
|
Lisa MacFarlane
|
|
12:50 PM -
1:05 PM |
Basic Lutetuim-177 Chemistry Masterclass
|
Mo Haskali
|
|
12:55 PM - 1:10 PM
|
National perspective of NMT role in Theranostics
|
Louise Campbell
|
|
1:05 PM -
1:20 PM |
Radionuclide Combination Therapies and
Patient Outcomes in Prostate Cancer |
Louise Emmett
|
|
1:10 PM - 1:25 PM
|
Technologist Roles and Considerations for Theranostics in the United States
|
Sarah Clements Holt
|
|
1:20 PM -
1:35 PM |
What is a Medical Physicist?
The unseen experts behind radiotherapy and theranostics |
Price Jackson
|
|
1:25 PM - 1:40 PM
|
From Vision to Reality: Delivering New Zealand’s First Regional Molecular
Imaging and Theranostics Centre with Patients experience at its core |
Prue Lamerton
|
|
1:35 PM -
1:50 PM |
Beyond Survival: Rethinking Outcomes in Prostate Cancer Care
Clinical trials, survivorship, and patient-reported experience |
Alicia Morgans
|
|
1:40 PM - 1:55 PM
|
Production and Supply of Lutetium-177
|
Robert Raposio
|
|
1:50 PM -
2:20 PM |
Panel Discussion
|
|
|
1:55 PM - 2:10 PM
|
Radiopharmaceutical development: Pre-clinical to clinical
|
Joseph Van De Garde
|
|
2:20 PM -
2:25 PM |
Thank you and Close
|
Elizabeth Medhurst
|
|
2:10 PM - 2:25 PM
|
Selecting the right trial and treatment for the patient
|
Shahneen Sandhu
|
|
|
|
|
|
2:25 PM - 2:40 PM
|
Clinical trial Co-ordination
|
Claire Martin
|
|
|
|
|
|
2:40 PM - 3:10 PM
|
Afternoon Tea
|
|
2:25 PM –
3:00 PM |
Afternoon Tea
|
||
|
3:10 PM - 5:00 PM
|
Theranostic Masterclass for Nuclear Medicine Technologists
| Part 2
Location: Level 7 Atrium 
|
|
3:00 PM -
4:30 PM |
PCFA Nurses Session Session 2
Location: Level 13 |
||
|
3:10 PM - 3:25 PM
|
Theranostic Equipment and qualification for trials
|
Brittany Emmerson
|
|
3:00 PM -
3:15 PM |
Tough Conversations: Patient Suitability for Lu-177 Therapy
Balancing hope, evidence, and realistic expectations |
Sebastian Eliceiry
|
|
3:25 PM - 3:40 PM
|
The Science of Dose: Understanding Dosimetry in Theranostics
|
Price Jackson
|
|
3:15 PM -
3:30 PM |
Modern Sequencing in mestatastic prostate cancer in 2026
Balancing survival benefit, toxicity, and patient selection |
Arun Azad
|
|
3:40 PM - 3:55 PM
|
Theranostic Innovations from GE HealthCare
|
GE
|
|
3:30 PM -
3:45 PM |
The Role of a Theranostics Nurse
Coordination, communication,
and care in targeted radionuclide therapy |
Elizabeth Medhurst
|
|
3:55 PM - 4:10 PM
|
Reading Beyond the Images: Clinical Decision-Making in Theranostics
|
Natalia Kovaleva
|
|
3:45 PM -
4:00 PM |
The Role of a Nuclear Medicine Technologist
Where technology,
radiation safety, and patient care intersect |
Lisa Macfarlane
|
|
4:10 PM - 4:25 PM
|
Radiation safety: beyond compliance
|
Leah Neeson
|
|
4:00 PM -
4:25 PM |
Panel Discussion
|
|
|
4:25 PM - 4:35 PM
|
Total Body PET: Installation & experience
|
Kenneth Yap
|
|
4:25 PM -
4:30 PM |
Thank you and Close
|
Elizabeth Medhurst
|
|
4:35 PM - 4:45 PM
|
Imaging in Motion: Why multi time-point imaging matters
|
Alicia Corlett
|
|
|
|
|
|
4:45 PM - 5:00 PM
|
Closing
|
Grace Kong
|
|
|
|
|
|
5:00 PM - 5:30 PM
|
Cancer Imaging Tours
Location: Level 5
|
|||||
|
6:30 PM - 8:30 PM
|
ProsTIC26 Welcome Reception
Many Origins, One Future: Working Together to Advance PSMA Theranostics Globally Proudly Sponsored by GE Healthcare Location: Victorian Immigration Museum |
|||||
Day 1
- Friday 4 September 2026
- Sofitel Melbourne on Collins
|
Time
|
Session
|
||
|---|---|---|---|
|
7:15 AM - 8:00 AM
|
Registration
Location: Sofitel Melbourne on Collins |
||
|
Session 1: PSMA Imaging in 2026
|
Session Chairs: Renu Eapen & Louise Emmett
|
||
|
8:00 AM - 8:15 AM
|
Welcome to ProsTIC26: Advancing Prostate Cancer Imaging and Theranostics
|
Professor Jason Payne (CEO Peter Mac)
Professor Michael Hofman Professor Phillip J. Koo (PCF) |
|
|
8:15 AM - 8:25 AM
|
Patient Perspective
|
Mr John Jennings
|
|
|
8:25 AM - 8:35 AM
|
From Discovery to Daily Practice: A Brief History of PSMA
|
Martina Benešová-Schäfer
|
|
|
8:35 AM - 8:45 AM
|
Choosing the Right PSMA Radiotracer: Ga-68 versus F-18 for My Patient?
|
Sidney Levy
|
|
|
8:45 AM - 8:55 AM
|
Standardising High-Quality PSMA PET Reporting
|
Matthias Eiber
|
|
|
8:55 AM - 9:05 AM
|
Will PSMA PET Replace Painful Prostate Biopsy? Yes
|
Yao Zhu
|
|
|
9:05 AM - 9:15 AM
|
Will PSMA PET Replace Painful Prostate Biopsy? No
|
Alberto Briganti
|
|
|
9:15 AM - 9:25 AM
|
Surgical PSMA-targeted approaches to prostate cancer
|
Tobias Maurer
|
|
|
9:25 AM - 9:35 AM
|
PSMA PET/CT for Diagnosis: PRIMARY2 study
|
Daniel Moon
|
|
|
9:35 AM - 9:45 AM
|
Q&A Session
|
||
|
9:45 AM - 10:15 AM
|
Morning Tea
|
||
|
Session 2: PSMA Multi-Disciplinary Tumor Board in Action Cases
|
Session Chair: Michael Hofman
|
||
|
10:15 AM - 11:00 AM
|
PSMA PET/CT: Case By Case (Panel 1)
|
|
|
|
11:00 AM - 11:45 AM
|
PSMA PET/CT: Case By Case (Panel 2)
|
|
|
|
11:45 AM - 12:45 PM
|
Lunch & Poster Viewing Session
|
Poster Presenters:
Jaspriya Bal Rian Hidayatullah Mary Anne Joseph Thomas Kryza Kaylee Molin Harish Nagaraj Girish Kumar Parida Raniv Rojo Sameer Taywade |
|
|
Session 3 : PSMA Plus: Value Adding to Each Case
|
Session Chairs: Roslyn Francis & Matthias Eiber
|
||
|
12:45 PM - 12:55 PM
|
PSMA PET for Risk Stratification
|
Andrei Iagaru
|
|
|
12:55 PM - 1:05 PM
|
PSMA Whole Body Quantification: How We Do It
|
Michael Hofman
|
|
|
1:05 PM - 1:15 PM
|
The benefits of post therapy SPECT/CT over PET/CT
|
Grace Kong
|
|
|
1:15 PM - 1:25 PM
|
Total Body PET/CT & PSMA
|
Michael Hofman
|
|
|
1:25 PM - 1:45 PM
|
2026 ProsTIC Saul Hertz Plenary
Two Isotopes That Changed Medicine:
Celebrating 85 Years of Radioiodine and 50 Years of FDG PET |
Andrei Iagaru
Michael Hofman |
|
|
1:45 PM - 1:55 PM
|
Q&A
|
||
|
Session 4: Lutetium-177 in 2026
|
Session Chairs: Shankar Siva & Alicia Morgans
|
||
|
2:00 PM - 2:10 PM
|
Appropriate Use of Lutetium PSMA in 2026
|
Arun Azad
|
|
|
2:10 PM - 2:20 PM
|
Lutetium PSMA in Oligometastatic Disease
|
Amar Kishan
|
|
|
2:20 PM - 2:30 PM
|
Should we Move Away From 6 Cycles Every 6 Weeks?
|
Louise Kostos
|
|
|
2:30 PM - 2:40 PM
|
Lu-PSMA Combinations: Which Combo will Rule?
|
Shahneen Sandhu
|
|
|
2:40 PM - 2:50 PM
|
Lu-PSMA: Prior or After Surgery? Is there a Role?
|
Renu Eapen
|
|
|
2:50 PM - 3:00 PM
|
Q&A
|
||
|
3:00 PM - 3:30 PM
|
Afternoon Tea
|
||
|
Session 5: Optimising Theranostics with New Atoms, New Targets
|
Session Chairs: Grace Kong & Mohammad Haskali
|
||
|
3:30 PM - 3:40 PM
|
Actinium-225 - pros and cons
|
Matthias Eiber
|
|
|
3:40 PM - 3:50 PM
|
Terbium-161 - pros and cons
|
Michael Hofman
|
|
|
3:50 PM - 4:00 PM
|
Astatine-211 - pros and cons
|
Tadashi Watabe
|
|
|
4:00 PM - 4:10 PM
|
Lead-203/212 - pros and cons
|
Michael Hofman
|
|
|
4:10 PM - 4:20 PM
|
Copper-64/67 - pros and cons
|
Louise Emmett
|
|
|
4:20 PM - 4:30 PM
|
New Targets: what will be the next PSMA?
|
Andrei Iagaru
|
|
|
4:30 PM - 4:40 PM
|
Q&A
|
||
|
7:00 PM - 11:00 PM
|
ProsTIC 2026 Conference Dinner
Proudly Sponsored by United Imaging Location: Sofitel Melbourne on Collins |
||
Day 2
- Saturday 5 September 2026
- Sofitel Melbourne on Collins
|
Time
|
Session
|
||
|---|---|---|---|
|
8:00 AM - 8:30 AM
|
Registration
Location: Sofitel Melbourne on Collins |
||
|
Session 6 : Radiopharmacutical Science & Preclinical Research
|
Session Chairs: Luc Furic & Thomas Handley
|
||
|
8:30 AM - 8:40 AM
|
Intrinsic Tumour Biology Drives Response to PSMA Radioligand
Therapy in Patient-Derived Models of Prostate Cancer |
Laura Porter
|
|
|
8:40 AM - 8:50 AM
|
Immune Response and Isotopes
|
Katie Owen
|
|
|
8:50 AM - 9:00 AM
|
Beyond the Scan: Correlative Biomarkers in the Theranostics Era
|
Edmond Kwan
|
|
|
9:00 AM - 9:10 AM
|
The Discovery and Development of Peptide Theranostics
Targeting the Oncoprotein ROR1 |
Joseph Van de Garde
|
|
|
9:10 AM - 9:20 AM
|
Engineering Radioligand Uptake for Improved Targeting in Prostate
and Breast Cancers |
Martina Benešová-Schäfer
|
|
|
9:20 AM - 9:30 AM
|
Developing Novel Platforms for Fluorine-18 labelling of radiopharmaceuticals
|
Talia Enright
|
|
|
9:30 AM - 9:40 AM
|
AI Grand Challenge
|
Price Jackson
|
|
|
9:40 AM - 9:50 AM
|
Q&A
|
||
|
Session 7: Rapid Fire Session (Best Selected Posters)
|
Session Chairs: Phil Koo & Dale Bailey
|
||
|
9:55 AM - 9:58 AM
|
PSMASegmentator: Open-source, AI-based software for PSMA PET/CT
automatic segmentation and prognostic biomarker extraction |
Joel Noble
|
|
|
9:58 AM - 10:01 AM
|
The use of external beam radiotherapy during treatment with
Lutetium-177 (177Lu)-PSMA-617 for metastatic castrate-resistant prostate cancer |
Sohyun Kim
|
|
|
10:01 AM - 10:04 AM
|
Prospective Evaluation of Amino Acid Co-Infusion for Renal Dose
Reduction During [177Lu]Lu-PSMA-I&T Therapy: Interim Results from the RENOGUARD Trial |
Zeyad Al-Ogaili
|
|
|
10:04 AM - 10:07 AM
|
Neoadjuvant ¹⁷⁷Lu-PSMA-1 Combined with Moderately
Hypofractionated Radiotherapy in High-Risk Localized Prostate Cancer (LU-EBRT): A Multicentric Phase I TiTE-CRM Study |
Genevieve Loos
|
|
|
10:07 AM - 10:10 AM
|
PETomics: Integrating PET Imaging and ctDNA Genomics via Deep Learning to
Predict Response to Lutetium‑177 PSMA‑617 in mCRPC Patients |
Mevan Ekanayake
|
|
|
10:10 AM - 10:13 AM
|
Dimethylaminoparthenolide augments the radiation response in prostate cancer
|
Katherine Morel
|
|
|
10:13 AM - 10:15 AM
|
Questions & Judges
|
||
|
10:15 AM - 10:45 AM
|
Morning tea
|
||
|
Session 8: PSMA Multi-Disciplinary Tumor Board in Action Cases
|
Session Chair: Michael Hofman
|
||
|
10:45 AM - 11:30 AM
|
Therapy cases (Expert Panel 1)
|
|
|
|
11:30 AM - 12:15 PM
|
Therapy cases (Expert Panel 2)
|
||
|
12:15 PM - 12:40 PM
|
Keynote: PSMA PET/CT and the Future of Prostate Cancer Trial Imaging
|
Alicia Morgans
|
|
|
12:40 PM - 1:40 PM
|
Lunch & Poster Viewing Session
|
Poster Presenters:
Alicia Corlett Harsha Doddihal Othon Gervasio Elena Gromova Hian Liang Huang Loren Katchel Malay Mishra Ali Mulayim Aftab Hasan Nazar Karol Osipowicz Aravind Ravi Kumar Minseok Suh Finn Von Eyben Cuhawijay Sathiyajith |
|
|
Session 9: How to Run Clinical Trials in Theranostics
|
Session Chairs: Andrew Scott & Lisa MacFarlane
|
||
|
1:40 PM - 1:50 PM
|
Behind Every Successful Theranostics Trial: The Clinical Trial Coordinator Perspective
|
Claire Martin
|
|
|
1:50 PM - 2:00 PM
|
From Protocol to Patient: The Nuclear Medicine Technologist’s Role in Theranostics Trials
|
Brittany Emmerson
|
|
|
2:00 PM - 2:10 PM
|
Making Theranostics Possible: Production, Quality Control and Translation
|
Mohammad Haskali
|
|
|
2:10 PM - 2:20 PM
|
Building National Capability: ARTnet, NIF and the Future of Human Molecular Imaging
|
Roslyn Francis
|
|
|
2:20 PM - 2:30 PM
|
Dosimetry for Phase 0/1 Trials
|
Dale Bailey
|
|
|
2:30 PM - 2:40 PM
|
Improving Quality-of-Life: what really matters for the patient
|
Brian Gonzalez
|
|
|
2:40 PM - 2:50 PM
|
Q&A
|
||
|
2:50 PM - 3:20 PM
|
Afternoon tea
|
||
|
Session 10: PSMA in Asia and Australia
|
Session Chairs: Declan Murphy & Brittany Emmerson
|
||
|
3:20 PM - 3:30 PM
|
PSMA imaging and theranostics in China today
|
Yao Zhu
|
|
|
3:30 PM - 3:40 PM
|
Lutetium PSMA in Australia: the Journey
|
Andrew Scott
|
|
|
3:40 PM - 3:50 PM
|
Nuclear Medicines Australia Perspective
|
Simone Leyden
|
|
|
3:50 PM - 4:00 PM
|
Conference Close & Thanks
|
Michael Hofman
|
|
*Program is subject to change
Subscribe for updates
Sign up to the mailing list to be the first to receive conference updates.
Copyright © . ProsTIC | All Rights Reserved